公开(公告)号：WO02094216A3

公开(公告)日：2003-10-16

申请号：PCT/US0215562

申请日：2002-05-15

Applicant: ALEXZA MOLECULAR DELIVERY CORP

Inventor： RABINOWITZ JOSHUA D ,  ZAFFARONI ALEJANDRO C

IPC: A61K9/00 ,  A61K9/12 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/473 ,  A61K31/49 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  F24V30/00 ,  A61K9/72

CPC classification number: A61K9/007 ,  A61K9/0073 ,  A61K9/12 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/473 ,  A61K31/49 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  F24J1/00

Abstract: The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing ephedrine or fenfluramine that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of ephedrine or fenfluramine. In a method aspect of the present invention, one of ephedrine or fenfluramine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of ephedrine or fenfluramine, to from a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering ephedrine or fenfluramine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of ephedrine or fenfluramine; and, b) a device that forms an ephedrine or fenfluramine containing aerosol from the composition, for inhalation by the mammal.

Abstract translation: 本发明涉及通过吸入途径递送兴奋剂。 具体来说，它涉及用于吸入治疗的含有麻黄素或芬氟拉明的气溶胶。 在本发明的组合物方面，气溶胶包含包含至少5重量％的麻黄碱或芬氟拉明的颗粒。 在本发明的方法方面，将麻黄碱或芬氟拉明中的一种通过吸入途径递送至哺乳动物。 该方法包括：a）加热组合物，其中所述组合物包含至少5重量％的麻黄素或芬氟拉明; 和b）允许蒸气冷却，由此形成包含由哺乳动物吸入的颗粒的冷凝气雾剂。 在本发明的试剂盒方面，提供了一种用于通过吸入途径向哺乳动物递送麻黄素或芬氟拉明的试剂盒，其包含：a）包含至少5重量％的麻黄碱或芬氟拉明的组合物; 和b）从所述组合物形成含有气溶胶的麻黄素或芬氟拉明用于哺乳动物吸入的装置。

公开(公告)号：WO02094246A3

公开(公告)日：2003-01-16

申请号：PCT/US0216558

申请日：2002-05-23

Applicant: ALEXZA MOLECULAR DELIVERY CORP

Inventor： RABINOWITZ JOSHUA D ,  ZAFFARONI ALEJANDRO C

IPC: A61K9/00 ,  A61K9/12 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/473 ,  A61K31/49 ,  A61K31/5517 ,  F24V30/00 ,  A61K9/72

CPC classification number: A61K9/007 ,  A61K9/0073 ,  A61K9/12 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/473 ,  A61K31/49 ,  A61K31/5517 ,  F24J1/00

Abstract: The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an NSAID. In a method aspect of the present invention, an NSAID is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an NSAID, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an NSAID through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an NSAID; and, b) a device that forms an NSAID aerosol from the composition, for inhalation by the mammal.

Abstract translation: 本发明涉及通过吸入途径递送非甾体抗炎药（NSAID）。 具体地说，它涉及用于吸入治疗的含有NSAID的气溶胶。 在本发明的组合物方面，气溶胶包含包含至少5重量％的NSAID的颗粒。 在本发明的方法方面，通过吸入途径将NSAID递送至哺乳动物。 该方法包括：a）加热组合物，其中所述组合物包含至少5重量％的NSAID，以形成蒸气; 和b）允许蒸气冷却，由此形成包含由哺乳动物吸入的颗粒的冷凝气雾剂。 在本发明的试剂盒方面，提供了用于通过吸入途径将NSAID递送至哺乳动物的试剂盒，其包含：a）包含至少5重量％的NSAID的组合物; 和b）从组合物形成NSAID气雾剂的装置，用于哺乳动物的吸入。

公开(公告)号：WO02094236A9

公开(公告)日：2006-11-16

申请号：PCT/US0216118

申请日：2002-05-20

Applicant: ALEXZA MOLECULAR DELIVERY CORP

Inventor： RABINOWITZ JOSHUA D ,  ZAFFARONI ALEJANDRO C

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/00 ,  A61K31/13 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/167 ,  A61K31/19 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/439 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/4525 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/473 ,  A61K31/48 ,  A61K31/485 ,  A61K31/49 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/505 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K45/00 ,  A61K47/48 ,  A61M11/00 ,  A61P15/10 ,  A61P21/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/32 ,  A61P29/00 ,  A61P31/04 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  F24V30/00

CPC classification number: A61K9/007 ,  A61K9/0073 ,  A61K9/12 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/19 ,  A61K31/192 ,  A61K31/195 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/473 ,  A61K31/485 ,  A61K31/49 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  A61K47/54 ,  A61M11/042 ,  A61M15/06 ,  A61M2205/8206 ,  F24J1/00 ,  Y10S514/923 ,  Y10S514/958

Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) Heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antipsychotic; and, b) a device that forms an antipsychotic containing aerosol from the composition, for inhalation by the mammal.

Abstract translation: 本发明涉及通过吸入途径递送抗精神病药。 具体地说，它涉及用于吸入治疗的含有抗精神病药的气溶胶。 在本发明的组合物方面，气溶胶包含包含至少5重量％的抗精神病药的颗粒。 在本发明的方法方面，通过吸入途径将抗精神病药物递送至哺乳动物。 该方法包括：a）加热组合物，其中组合物包含至少5重量％的抗精神病药物以形成蒸气; 和b）允许蒸气冷却，由此形成包含由哺乳动物吸入的颗粒的冷凝气雾剂。 在本发明的试剂盒方面，提供了一种用于通过吸入途径将抗精神病药物递送至哺乳动物的试剂盒，其包括：a）包含至少5重量％的抗精神病药的组合物; 和b）从该组合物形成含有气溶胶的抗精神病药物的装置，用于哺乳动物的吸入。

公开(公告)号：WO02094219A3

公开(公告)日：2003-03-06

申请号：PCT/US0216398

申请日：2002-05-22

Applicant: ALEXZA MOLECULAR DELIVERY CORP

Inventor： RABINOWITZ JOSHUA D ,  ZAFFARONI ALEJANDRO C

IPC: A61K9/00 ,  A61K9/12 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/473 ,  A61K31/49 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  F24V30/00 ,  A61K9/72 ,  A61K31/505

CPC classification number: A61K9/007 ,  A61K9/0073 ,  A61K9/12 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/473 ,  A61K31/49 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/519 ,  A61K31/53 ,  A61K31/551 ,  A61K31/5517 ,  F24J1/00

Abstract: The present invention relates to the delivery of erectile dysfunction drugs through an inhalation route. Specifically, it relates to aerosols containing erectile dysfunction drugs that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an erectile dysfunction drug. In a method aspect of the present invention, an erectile dysfunction drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an erectile dysfunction drug, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an erectile dysfunction drug through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an erectile dysfunction drug; and, b) a device that forms an erectile dysfunction drug aerosol from the composition, for inhalation by the mammal.

Abstract translation: 本发明涉及通过吸入途径递送勃起功能障碍药物。 具体来说，它涉及含有用于吸入治疗的勃起功能障碍药物的气溶胶。 在本发明的组合物方面，气溶胶包含包含至少5重量％的勃起功能障碍药物的颗粒。 在本发明的方法方面，勃起功能障碍药物通过吸入途径递送至哺乳动物。 该方法包括：a）加热组合物，其中所述组合物包含至少5重量％的勃起功能障碍药物，以形成蒸汽; 和b）允许蒸气冷却，由此形成包含由哺乳动物吸入的颗粒的冷凝气雾剂。 在本发明的试剂盒方面，提供了一种用于通过吸入途径向哺乳动物递送勃起功能障碍药物的试剂盒，其包括：a）包含至少5重量％的勃起功能障碍药物的组合物; 和b）由组合物形成勃起功能障碍药物气雾剂的装置，用于哺乳动物的吸入。

公开(公告)号：WO02094244A2

公开(公告)日：2002-11-28

申请号：PCT/US0216458

申请日：2002-05-21

Applicant: ALEXZA MOLECULAR DELIVERY CORP

Inventor： KIM JOHN J ,  RABINOWITZ JOSHUA D ,  ZAFFARONI ALEJANDRO C

IPC: A61K9/00 ,  A61K9/12 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/473 ,  A61K31/49 ,  A61K31/5513 ,  A61K31/5517 ,  F24V30/00 ,  A61K9/72

CPC classification number: A61K9/007 ,  A61K9/0073 ,  A61K9/12 ,  A61K31/137 ,  A61K31/138 ,  A61K31/165 ,  A61K31/192 ,  A61K31/216 ,  A61K31/27 ,  A61K31/404 ,  A61K31/405 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/423 ,  A61K31/473 ,  A61K31/49 ,  A61K31/5513 ,  A61K31/5517 ,  F24J1/00

Abstract: The present invention relates to the delivery of benzodiazepines through an inhalation route. Specifically, it relates to aerosols containing benzodiazepines that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a benzodiazepine. In a method aspect of the present invention, a benzodiazepine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a benzodiazepine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering a benzodiazepine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of a benzodiazepine; and, b) a device that forms a benzodiazepine containing aerosol from the composition, for inhalation by the mammal.

Abstract translation: 本发明涉及通过吸入途径递送苯二氮卓类药物。 具体地说，它涉及用于吸入治疗的含有苯并二氮杂类的气溶胶。 在本发明的组合物方面，气雾剂包含包含至少5重量％苯并二氮杂的颗粒。 在本发明的方法方面，通过吸入途径将苯二氮卓类药物递送至哺乳动物。 该方法包括：a）加热组合物，其中组合物包含至少5重量％的苯并二氮杂以形成蒸汽; 和b）允许蒸气冷却，由此形成包含由哺乳动物吸入的颗粒的冷凝气雾剂。 在本发明的试剂盒方面，提供了一种用于将苯二氮卓通过吸入途径输送给哺乳动物的试剂盒，其包括：a）包含至少5重量％的苯并二氮杂的组合物; 和b）从组合物形成含有苯并二氮杂的气溶胶的装置，用于哺乳动物的吸入。